Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5- carboxamide, an agonist of the α7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: Synthesis and structure-activity relationship

Journal of Medicinal Chemistry

Volumn 49, Issue 14, 2006, Pages 4425-4436

  Wishka, Donn G ^a   Walker, Daniel P ^a   Yates, Karen M ^a   Reitz, Steven C ^a   Jia, Shaojuan ^a   Myers, Jason K ^a   Olson, Kirk L ^a   Jacobsen, E Jon ^a   Wolfe, Mark L ^a   Groppi, Vincent E ^a   Hanchar, Alexander J ^a   Thornburgh, Bruce A ^a   Cortes Burgos, Luz A ^a   Wong, Erik H F ^a   Staton, Brian A ^a   Raub, Thomas J ^a   Higdon, Nicole R ^a   Wall, Theron M ^a   Hurst, Raymond S ^a   Walters, Rodney R ^a   Hoffmann, William E ^a   Hajos, Mihaly ^a   Franklin, Stanley ^a   Carey, Galen ^a   Gold, Lisa H ^a   Cook, Karen K ^a   Sands, Steven B ^a   Zhao, Sabrina X ^a   Soglia, John R ^a   Kalgutkar, Amit S ^a   Arneric, Stephen P ^a   Rogers, Bruce N ^a   more..

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA7 NICOTINIC RECEPTOR AGONIST; CARBAMIC ACID DERIVATIVE; N (1 AZABICYCLO[2.2.2]OCT 3 YL)FURO[2,3 C]PYRIDINE 5 CARBOXAMIDE; NICOTINE; NICOTINIC AGENT; PHA 543613; PYRIDINE DERIVATIVE; QUINUCLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUDITORY SYSTEM; BRAIN TISSUE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; OBJECT RELATION; RAT; RECOGNITION; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION;

ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; BIOLOGICAL AVAILABILITY; BRAIN; COGNITION DISORDERS; DRUG STABILITY; ETHER-A-GO-GO POTASSIUM CHANNELS; EVOKED POTENTIALS, AUDITORY; HUMANS; LEARNING; MALE; MEMORY; MICROSOMES, LIVER; NEURONS; NICOTINIC AGONISTS; NOOTROPIC AGENTS; PATCH-CLAMP TECHNIQUES; QUINUCLIDINES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC; RECOGNITION (PSYCHOLOGY); SCHIZOPHRENIA; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33745808357     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0602413     Document Type: Article

References (75)

1. (a) Holden, C. Deconstructing Schizophrenia. Science 2003, 299, 333-335.
2. (b) Sawa, A.; Snyder, S. H. Schizophrenia: Diverse Approaches to a Complex Disease. Science 2002, 296, 692-695.
3. Green, M. F.; Braff, D. L. Translating the Basic and Clinical Cognitive Neuroscience of Schizophrenia to Drug Development and Clinical Trials of Antipsychotic Medications. Biol. Psychiatry 2001, 49, 374-384.
4. Levin, E. D.; Simon, B. B. Nicotinic Acetylcholine Involvement in Cognitive Function in Animals. Psychopharmacology 1998, 138, 217-230.
5. Lead nAChR references: (a) Dani, J. A. Overview of Nicotinic Receptors and Their Roles in the Central Nervous System. Biol. Psychiatry 2001, 49, 166-174.
6. (b) Picciotto, M. R.; Caldarone, B. J.; King, S. L.; Zachariou, V. Nicotinic Receptors in the Brain; Links between Molecular Biology and Behavior. Neuropsychopharmacology 2000, 22, 451-465.
7. (c) Handbook of Experimental Pharmacology: Neuronal Nicotinic Receptors; Clementi, F., Fornasari, D., Gotti, C., Eds.; Springer: New York, 2000.
8. (d) Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities; Arneric, S. P.; Brioni, J. D., Eds.; Wiley-Liss: New York, 1999.
9. (a) Freedman, R.; Hall, M.; Adler, L. E.; Leonard, S. Evidence in Post-Mortem Brain Tissue for Decreased Numbers of Hippocampal Nicotinic Receptors in Schizophrenia. Biol. Psychiatry 1995, 38, 22-33.
10. (b) Marutle, A.; Zhang, X.; Court, J.; Piggott, M.; Johnson, M.; Perry, R.; Perry, E.; Nordberg, A. Laminar Distribution of Nicotinic Receptor Sub-types in Cortical Regions in Schizophrenia. J. Chem. Neuroanat. 2000, 22, 115-126.
11. (a) Guan, Z. Z.; Zhang, X.; Blennow, K.; Nordberg, A. Decreased Protein Level of Nicotinic Receptor A? Subunit in the Frontal Cortex from Schizophrenic Brain. NeuroReport 1999, 10, 1779-1782.
12. (b) Court, J.; Spurden, D.; Lloyd, S.; McKeith, I.; Ballard, C.; Cairns, N.; Kerwin, R.; Perry, R.; Perry, E. Neuronal Nicotinic Receptors in Dementia with Lewy Bodies and Schizophrenia: α-Bungarotoxin and Nicotine Binding in the Thalamus. J. Neurochem. 1999, 73, 1590-1597.
13. Freedman, R.; Coon, H.; Myles-Worsley, M.; Orr-Urtreger, A.; Olincy, A.; Davis, A.; Polymeropoulos, M.; Holik, J.; Hopkins, J.; Hoff, M.; Rosenthal, J.; Waldo, M. C.; Reimherr, F.; Wender, P.; Yaw, J.; Young, D. A.; Breese, C. R.; Adams, C.; Patterson, D.; Adler, L. E.; Kruglyak, L.; Leonard, S.; Byerley, W. Linkage of a Neurophysiological Deficit in Schizophrenia to a Chromosome 15 Locus. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 587-592.
14. Adler, L. E.; Hoffer, L. D.; Wiser, A.; Freedman, R. Normalization of Auditory Physiology by Cigarette Smoking in Schizophrenic Patients. Am. J. Psychiatry 1993, 150, 1856-1861.
15. Goff, D. C.; Henderson, D. C.; Amico, E. Cigarette Smoking in Schizophrenia: Relationship to Psychopathology and Medication Side Effects. Am. J. Psychiatry 1992, 149, 1189-1194.
16. Ripoll, N.; Bronnec, M.; Bourin, M. Nicotinic Receptors and Schizophrenia. Curr. Med. Res. Opin. 2004, 20, 1057-74.
17. (a) Stevens, K. E.; Wear, K. D. Normalizing Effects of Nicotine and a Novel Nicotinic Agonist on Hippocampal Auditory Gating in Two Animal Models. Pharmacol., Biochem. Behav. 1997, 57, 869-874.
18. (b) Stevens, K. E.; Kem, W. R.; Mahnir, V. M.; Freedman, R. Selective α7-Nicotinic Agonists Normalize Inhibittion of Auditory Response in DBA Mice. Psychopharmacologv 1998, 136, 320-327.
19. Hajós, M.; Hurst, R, S.; Hoffmann, W. E.; Krause, M.; Wall, T. M.; Higdon, N. R.; Groppi, V. E. The Selective α7 nAChR Agonist PNU-282, 987 Enhances GABAergic Synaptic Activity in Brain Slices and Restores Auditory Gating Deficits in Anesthetized Rats. J. Pharmacol. Exp. Ther. 2005, 312, 1213-1222.
20. Kitagawa, H.; Takenouchi, T.; Azuma, R.; Wesnes, K. A.; Kramer, W. G.; Clody, D. E.; Burnett, A. L. Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology 2003, 28, 542-551.
21. Nagamoto, H. T.; Adler, L. E.; McRae, K. A.; Huettl, P.; Cawthra, E.; Gerhardt, G.; Hea, R.; Griffith, J. Auditory P50 in Schizophrenics on Clozapine: Improved Gating Parallels Clinical Improvement and Changes in Plasma 3-Methoxy-4-hydroxyphenyl-glycol. Neuropsychobiology 1999, 39, 10-17.
22. Reviews: (a) Jensen, A. A.; Frolund, B.; Liljefors, T.; Krogsgaard-Larsen, P. Neuronal Nicotinic Acetylcholine Receptors: Structural Revelations, Target Identifications, and Therapeutic Inspirations. J: Med. Chem. 2005, 48, 4705-4745.
23. (b) Hashimoto, K.; Koike, K.; Shimizu, E.; Iyo, M. α7 nicotinic receptor agonists as potential therapeutic drugs for schizophrenia. Curr. Med. Chem. 2005, 5, 171-184.
24. (c) Bunnelle, W. H.; Dart, M. J.; Schrimpf, M. R. Design of Ligands for the Nicotinic Acetylcholine Receptors: The Quest for Selectivity. Curr. Med. Chem. 2004, 4, 299-334.
25. (d) Romanelli, M. N.; Gualtieri, F. Cholinergic Nicotinic Receptors: Competitive Ligands, Allosteric Modulators, and Their Potential Applications. Med. Res. Rev. 2003, 23, 393-426.
26. (e) Astles, P. C.; Baker, S. R.; Boot, J. R.; Broad, L. M.; Dell, C. P.; Keenan, M. Recent Progress in the Development of Subtype Selective Nicotinic Acetylcholine Receptor Ligands. Curr. Drug Targets: CNS Neurol. Disord. 2002, 1, 337-348.
27. (f) Schmitt, J. D. Exploring the Nature of Molecular Recognition in Nicotinic Acetylcholine Receptors. Curr. Med. Chem. 2000, 7, 749-800. Also see references cited within these papers.
28. (a) Meyer, E. M.; Tay, E. T.; Papke, R. L.; Meyers, C.; Huang, G.-L.; De Fiebre, C. M. 3-[2,4-Dimethoxybenzylidene]anabaseine (DMXB) selectively activates rat alpha 7 receptors and improves memory-related behaviors in a mecamylamine-sensitive manner. Brain Res. 1997, 768, 49-56.
29. (b) deFiebre, C. M.; Meyer, E. M.; Henry, J. C.; Muraskin, S. I.; Kern, W. R.; Papke, R. L. Characterization of a series of anabaseine-derived compounds reveals that the 3-(4)-dimethylaminocinnamylidine derivative is a selective agonist at neuronal nicotinic alpha7/1251-bungarotoxin receptor subtypes. Mol. Pharmacol. 1995, 47, 164-171.
30. Mullen, G.; Napier, J.; Balestra, M.; DeCory, T.; Hale, G.; Macor, J.; Mack, R.; Loch, J.; Wu, E.; Kover, A.; Verhoest, P.; Sampognaro, A.; Phillips, E.; Zhu, Y.; Murray, R.; Griffith, R.; Blosser, J.; Gurley, D.; Machulskis, A.; Zongrone, J.; Rosen, A.; Gordon, J. (-)-Spiro-[1-azabi-cyclo[2.2.2]octane-3. 5′-oxazolidin-2′-one], a Conformationally Restricted Analog of Acetylcholine. Is a Highly Selective Full Agonist at the a7 Nicotinic Acetylcholine Receptor. J. Med. Chem. 2000, 43, 4045-4050.
31. (a) Macor, J.; Wu, E. Azabicyclic Esters of Carbamic Acids Useful in Therapy. PCT Int. Appl. WO9730998, August 28, 1997.
32. (b) Guendisch, D.; Andrae, M.; Munoz, L.; Tilotta, M. C. Synthesis and evaluation of phenylcarbamate derivatives as ligands for nicotinic acetylcholine receptors. Bioorg. Med. Chem. 2004, 12, 4953-4962.
33. Bodnar, A. L.; Cortes-Burgos, L. A.; Cook, K. K.; Dinh, D. M.; Groppi, V. E.; Hajos, M.; Higdon, N. R.; Hoffmann, W. E.; Hurst, R. S.; Myers, J. K.; Rogers, B. N.; Wall, T. M.; Wolfe, M. L. Wong. E. Discovery and SAR of Quiniclidine Benzamides as Agonists of α7 Nicotinic Acetylcholine Receptors. J. Med. Chem. 2005,48, 905-908.
34. Tatsumi, R.; Seio, K.; Fujio, M.; Katayama, J.; Horikawa, T.; Hashimoto, K.; Tanaka, H. (+)-3-[2-(Benzo[b]thiophen-2-yl)-2-oxoethyl]-1-azabicyclo[2.2.2] octane as potent agonists for the α7 nicotinic acetylcholine receptor. Bioorg. Med. Chem. Lett. 2004, 14, 3781-3784.
35. Biton, B.; Bergis, O. E.; Galli, F.; Nedelec, A.; Lochead, A.; Jegham. S.; Lanneau, C.; Granger, P.; Leonardon, J.; Avenet, P.; Godet, D.; Coste, A.; Vig, X.; Oury-Donat, F.; George, P.; Soubri, P.; Griebel, G.; Scatton B. SSR180711A, A novel selective α7 nicotinic receptor partial agonist. I. Binding profile and in vitro functional characterization. Presented at the 34th Annual Neuroscience Meeting, San Diego. California, October 23-27, 2004: Abstract 583.1.
36. See Supporting Information for full experimental details.
37. (a) Wishka, D. G.; Reitz, S. C.; Piotrowski, D. W.; Groppi, V. E., Jr. WO 2002/100857, 2002.
38. (b) Walker, D. P.; Wishka, D. G.; Corbett, J. W.; Rauckhorst, M. R.; Piotrowski, D. W.; Groppi, V. E. WO 2002/100858, 2002.
39. (c) Walker, D. P.; Piotrowski, D. W.; Jacobsen, E. J.; Acker, B. A.; Groppi, V. E. WO 2003/070731, 2003,
40. (d) Rogers, B. N.; Piotrowski, D. W.; Walker, D. P.; Jacobsen, E. J.; Acker, B. A.; Wishka, D. G.; Groppi, V. E. WO 2003/070732, 2003.
41. The α7 5HT3 chimera assay was previously established as predictive of native α7 nAChR activity; see refs 12 and 19.
42. Kalgutkar, A. S.; Gardner, I.; Obach, R. S.; Shaffer, C. L.; Callegari, E.; Henne, K.; Mutlib, A.; Dalvie, D.; Lee, J.; Nakai, Y.; O'Donnell J.; Boer, J.; Harriman, S. A Comprehensive Listing of Bioactivation Pathways of Organic Functional Groups. Can. Drug Metab. 2005, 6, 161-225.
43. Sirota, P.; Mosheva, T.; Shabtay, H.; Giladi, N.; Korczyn, A. D. Use of the Selective Serotonin 3 Receptor Antagonist Ondansetron in the Treatment Of Neuroleptic-induced Tardive Dyskinesia. Am. J. Psychiatry 2000, 157, 287-289.
44. (a) Viskin, S. Long QT Syndromes and Torsade de Pointes. Lancet 1999, 354, 1625-1633.
45. (b) Mitcheson, J. S.; Chen, J.; Lin, M.; Culberson, C; Sanguinetti, M. C. A Structural Basis for Drug-Induced Long QT Syndrome. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 12329-12333.
46. Compounds screened in Chan Test, hERG Block Comparitor Screen.
47. Sanguinetti, M. C.; Mitcheson, J. S. Predicting Drug-hERG Channel Interactions That Cause Acquired Long QT Syndrome. Trends Pharmacol. Sci. 2005, 26, 119-124.
48. Soglia, J. R.; Harriman, S. P.; Zhao, S.; Barberia, J.; Cole, M. J.; Boyd, J. G.; Contillo, L. G. The Development of a Higher Throughput Reactive Intermediate Screening Assay Incorporating Microbore Liquid Chromatography Microelectrospray lonization Tandem Mass Spectrometry and Glutathione Ethyl Ester as an in vitro Conjugating Agent. J. Pharm. Biomed. Anal. 2004, 36, 105-116.
49. (a) See Supporting Information for LC/MS/MS analysis of NADPH-supplemented human liver microsomal incubations containing 13 and GSH-EE, and for the molecular weight of this conjugate.
50. Baillie, T. A.; Davis, M. R. Mass Spectrometry in the analysis of glutathione conjugates. Biol. Mass Spectrom. 1993, 22, 319-325.
51. Dalvie, D. K.; Kalgutkar, A. S.; Khojasteh-Bakht, S. C.; Obach, R. S.; O'Donnell, J. P. Biotransformation reactions of five-membered aromatic heterocyclic rings. Chem. Res. Toxicol. 2002, 15, 269-299.
52. Garberg, P.; Ball, M.; Borg, N.; Cecchelli, R.; Fenart, L.; Hurst, R. D.; Lindmark, T.; Mabondzo, A.; Nilsson, J. E.; Raub, T. J.; Stanimirovic, D.; Terasaki, T.; Oeberg, J.-O.; Oesterberg, T. In Vitro Models for the Blood-Brain Barrier. Toxicol. in Vitro 2005, 19, 299-334.
53. Seguela, P.; Wadiche, J.; Dineley-Miller, K.; Dani, J. A.; Patrick, J. W. Molecular Cloning, Functional Properties, and Distribution of Rat Brain α7: A Nicotinic Cation Channel Highly Permeable to Calcium. J. Neurosci. 1993, 13, 596-604.
54. 22
55. Krause, M.; Hoffmann, W. E.; Hajos, M. Auditory Sensory Gating in Hippocampus and Reticular Thalamic Neurons in Anaesthetized Rats. Biol. Psychiatry 2003, 53, 244-253.
56. (a) Ellenbroek, B. A.; de Bruin, N. M.; van Den Kroonenburg, P. T.; van Luijtelaar, E. L.; Cools, A. The effects of early maternal deprivation on auditory information processing in adult Wistar rats. Biol. Psychiatry 2004, 55, 701-707.
57. (b) O'Neill, H. C.; Rieger, K.; Kern, W. R.; Stevens, K. E. DMXB, an alpha? nicotinic agonist, normalizes auditory gating in isolation-reared rats. Psychopharmacology 2003, 169, 332-339.
58. (c) Stevens, K. E.; Kern, W. R.; Freedman, R. Selective alpha 7 nicotinic receptor stimulation normalizes chronic cocaine-induced loss of hippocampal sensory inhibition in C3H mice. Biol. Psychiatry 1999, 46, 1443-1450.
59. (a) Ennaceur, A.; Delacour, J. A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav. Brain Res. 1988, 31, 47-59.
60. (b) Moser, P. C; Bergis, O. E.; Jegham, S.; Lochead, A.; Duconseille, E.; Terranova, J.; Caille, D.; Berque-Bestel, I.; Lezoualc'h, F.; Fischmeister, R.; Dumuis, A.; Bockaert, J.; George, P.; Soubrié, P.; Scatton, P. SL65-0155, A Novel 5-HT4 Receptor Partial Agonist with Potent Cognition-Enhancing Properties. J. Pharmacol. Exp. Ther. 2002, 502, 731-741.
61. (a) Prickaerts, J.; Sik, A.; van der Staay, F. J.; de Vente, J.; Blokland, A. Dissociable effects of acetylcholinesterase inhibitors and phosphodiesterase type 5 inhibitors on object recognition memory: acquisition versus consolidation. Psychopharmacology 2005 177, 381-390.
62. (b) Moser, P. C.; Bergis, O. E.; Jegham, S.; Lochead, A.; Duconseille, E.; Terranova, J.; Caille, D.; Berque-Bestel, I.; Lezoualc'h, F.; Fischmeister, R.; Dumuis, A.; Bockaert, J.; George, P.; Soubrié, P.; Scatton, P. SL65-0155, a Novel 5-HT4 Receptor Partial Agonist with Potent Cognition-Enhancing Properties. J. Pharmacol Exp. Ther. 2002, 502, 731-741.
63. Still, W. C.; Kahn, M.; Mitra, A. Rapid Chromatographic Technique for Preparative Separations with Moderate Resolution. J. Org. Chem. 1978, 43, 2923.
64. (a) Carpino, L. A. 1-Hydroxy-7-azabenzotriazole. An Efficient Peptide Coupling Additive. J. Am. Chem. Sac. 1993, 115, 4397-4398.
65. (b) Downing, S. V.; Aguilar, E.; Meyers, A. I. Total Synthesis of Bistratamide D. J. Org. Chem. 1999, 64, 826-831.
66. Welstead, W. J., Jr. Enhancing Memory or Correcting Memory Deficiency with Arylamido- and Arylthioamidoazabicycloalkanes. U.S. Patent 4,605,652, August 12, 1986.
67. Amin, H. B.; Awad, A. A.; Archer, W. J.; Taylor, R. Electrophilic Aromatic Substitution. Part 33. Partial Rate Factors for Protiodetritiation of Benzo[b]thiophen; the Resonance-Dependent Reactivity of the Ring Positions. J. Chem. Soc., Perkin Trans. 2 1982, 1489-1492.
68. Shiotani, S.; Taniguchi, K. Furopyridines. XXI. Synthesis of Cyano Derivatives of Furo-[2,3-b]-, -[2,3-c]- and -[3,2-c]pyridine and Their Conversion to Derivatives Having Another Carbon-Substituent. J. Heterocycl. Chem. 1997, 34, 493-499.
69. Soglia, J. R.; Harriman, S. P.; Zhao, S.; Barberia, J.; Cole, M. J.; Boyd, J. G.; Contillo, L. G. The Development of a Higher Throughput Reactive Intermediate Screening Assay Incorporating Micro-bore Liquid Chromatography Micro-electrospray lonization Tandem Mass Spectrometry and Glutathione Ethyl Ester as an in Vitro Conjugating Agent. J. Pharm. Blamed. Anal. 2004, 36, 105-116.
70. Obach, R. S.; Baxter, J. G.; Liston, T. E.; Silber, B. M.; Jones, B. C.; Macintyre, F.; Ranee, D. J.; Wastall, P. The Prediction of Human Pharmacokinetic Parameters from Preclinical and in-Vitro Metabolism Data. J. Pharmacol. Exp. Ther. 1997, 283, 46-58.
71. Fitch, R. W.; Xiao, Y.; Kellar, K. J.; Daly, J. W. Membrane potential Fluorescence: A Rapid and Highly Sensitive Assay for Nicotinic Receptor Channel Function. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 4909-4914.
72. Pabreza, L. A.; Dhawan, S.; Kellar, K. J. [3H]cytisine binding to nicotinic cholinergic receptors in brain. Mol. Pharmacol. 1991, 39, 9-12.
73. Hurst, R. S.; Higdon, N. R.; Lawson, J. A.; Clark, M. A.; Rutherford-Root, K. L.; McDonald, W. G.; Haas, J. V.; McGrath, J. P.; Meglasson, M. D. Dopamine receptor agonists differ in their actions on cardiac ion channels. Eur. J. Pharmacol. 2003, 482, 31-37.
74. Paxinos, G.; Watson, C. The Rat Brain in Stereotaxic Coordinates; Academic Press: Sydney, 1986.
75. Moser, P. C.; Bergis, O. E.; Jegham, S.; Lochead, A.; Duconseille, E.; Terranova, J.; Caille, D.; Berque-Bestel, I.; Lezoualc'h, F.; Fischmeister, R.; Dumuis, A.; Bockaert, J.; George, P.; Soubrié, P.; Scatton, P. SL65-0155, a Novel 5-HT4 Receptor Partial Agonist with Potent Cognition-Enhancing Properties. J. Pharmacol. Exp. Ther. 2002, 302, 731-741.